Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Any expectations that Gerald owed us news this week (or last) are just incorrect. Gerald tweeted that they would get the latest BD results back in two weeks (that was Monday).
BTW:When did he cite a specific date as to when news was going to be released to the shareholders? If Gerald just got the Assay results (on Monday); how do we know what negotiations are in place between the two companies. More importantly Geralds may have lots of negotiating options with other parties who could potentially be in the mix as well.
The only expectations that are being set are by impatient shareholders; Gerald has tweeted enough hints (and literal and physical feedback as to how the Assay is performing). We will get our answers when company mgt. is ready to release them....and if you don't think Macro trends have anything to do with timing of news release...you would be kidding yourself.
Just a note: Jim Cramer instructed his viewing audience to SELL and take profits on all the small biotechs (last night on his show). Between the Govt. fallout and dilution here...we sure have a lot of negative cross currents.
On a brighter note: Biotech stocks are news driven; fundamentally, we have all of the same potential (just with a higher share base). Management have every intention to move us above $.10; or they wont get their extra $8mm in financing. Moreover, we are in uncharted territory with MANF...if things all work out.......getting to $.20 (and way beyond) is very attainable to say the least.
Lastly, I would not knock Gerald on the timing of the LymPro news release; just ridiculous timing to update the market this week (but as the markets are stabilizing; next week should be a more healthy backdrop.).
If Amarantus Mgt. was not interested in a long term relationship with BD; I am doubtful that much time would be spent on future marketability.
I am expecting a L/T relationship with BD (although Amarantus does not require a relationship with BD to move forward; it will most certainly be in their best interest since BD has one of the most significant and best global distribution networks in the world (for a Diagnostic product).
Geralds tweet on Sept. 18th:
"Many important business & scientific topics were discussed including the current status of the assay, & ways to improve its marketability?
The PPS held above 50 day moving avg. ($.0525 for a 3rd day in a row). I understand that it should have performed better on a huge up day; but our time will come. GLTA!!!
Nice post dubbya.
Gerald tweeted two weeks ago that the Assay was performing "Very well". I really hope it stays above 90% (as stating that reality that performs very well has set a high expectation). As always; I am keeping my personal expectations in check until the real news hits.
We need a big win on LymPro; it will certainly be the "game changer" that Jason Napodano has always referred to ...the credibility for Mgt. here will be huge as well.
Its never a dumb question to ask; only an important question.. that does not get asked ..is considered dumb.
Gerald had tweeted that BD was to provide a BD report within 2 weeks (so I believe today was exactly two weeks). However, who knows how long Gerald (Mgt.) will take to review, react, process and eventually communicate to shareholders.
The relationship has some potential complexities; are these parties in a continuous negotiation phase, how is their relationship defined going forward, who will distribute the commercialized product (if AMBS Mgt. wants BD to do so), what enhancements could be made to improve the product, etc.
The PPS bounced off the 50 day moving avg. two days in a row (at around $.0525); I wish you luck in getting those lower prices.
See ya! I will "Hold for the Gold" instead of you (your favorite quote). Thanks for passing the torch.
You are correct with that assumption. He seemed to be that person who claims to have all that inside info (and I agree it seems to be that same person on Yahoo right now).
Thanks JPetro. Facts are Facts! Its a shame that some here have to work hard to squash mis-information.
I trust very few posters here anymore; but you sir are certainly one of them.
I believe that Mgt. wont convert until the have some sustained period above $.10 (at least for a short while). Also, I know a PR will more than likely be released confirming that the Warrants were converted.
How does it affect the PPS?; I hope Gerald would at least try to sustain some positive news (of some sort; but no guarantees). I would be truly disappointed if we don't make it above $.10 and sustain it or trend higher.
The jury is still out here; so much promise but we are badly lacking in any material news (perhaps one day soon). Even with close to $700mm O/S (a $.20 PPS is only a $140 market cap)...which is relatively small in the scheme of market cap. valuations (for successful biotech companies).
As there has been a lot of confusion lately (recent financing deals); it would be truly awesome if Jason Napodano (Zacks analyst) would update his analyst report. I am guessing he is waiting for some additional catalysts before finalizing it (it would be very cool to get an official buy recommendation as well).
...That is correct. I believe for Mgt. to receive the total $11 million in possible financing; they only got $3mm so far; unless the PPS trades above $.10.
Therefore; the Mgt. team should be very motivated to get us at least above $.10 to trigger the remaining $8mm in funding.
Nasdaq listing requirements are minimum $2 (to regain compliance if your stock falls below the minimum for so many days; it must come back over $1 to regain compliance.
New Nasdaq $2 / $3 Initial Price Listing Standards
As a quick follow up on this topic from a few months ago (prior post can be read here), the SEC has approved alternatives to Nasdaq's historical $4 minimum bid price listing standard. Under the new alternative listing standards, a security may qualify for listing on the Nasdaq Capital Market if:
$3/share price -- for at least five consecutive business days prior to approval, the security has a minimum closing price of at least $3 per share and the issuer has either: Equity Standard: (A) stockholders' equity of at least $5M; (B) market value of publicly held shares of at least $15M; and (C) a two year operating history; or
Net Income Standard: (A) net income from continuing operations of $750,000 in the most recently completed fiscal year or in two of the three most recently completed fiscal years; (B) stockholders' equity of at least $4M; and (C) market value of publicly held shares of at least $5 million; or
$2/share price -- for at least five consecutive business days prior to approval, the security has a minimum closing price of at least $2 per share and the issuer has (A) market value of listed securities of at least $50M; (B) stockholders' equity of at least $4M; and (C) market value of publicly held shares of at least $15M.
In addition, the issuer must also demonstrate that it has:
Net tangible assets in excess of $2M if it has been in continuous operation for at least three years;
Net tangible assets in excess of $5M if it has been in continuous operation for less than three years; or
Average revenue of at least $6M for the last three years.
Nasdaq-listed securities have historically not been regulated as "penny stocks" (which subject broker-dealers trading in them to additional disclosure and other requirements) because of the exception for securities registered on a national securities exchange that, among other things, required a minimum bid price of $4 per share at initial listing. NYSE Amex benefits from a "grandfather" exception that permits lower initial prices. With Nasdaq's new alternative listing standards, it can compete with the NYSE Amex for listings in the $2-3 range. However, it is possible that companies listing under these lower standards may become "penny stocks."
- See more at: http://www.lexisnexis.com/legalnewsroom/securities/b/securities/archive/2012/04/27/new-nasdaq-2-3-initial-price-listing-standards.aspx#sthash.i5siLDn8.dpuf
Reverse Split example:
The company: Zalicus (a small biotech company) did a 6 for 1 R/S very recently. What caught my attention was the minimum per share bid at $1. I need to do more due diligence; but I thought it was $2. Most importantly, if its only a $1; it will soften the blow should a R/S be necessary here.
Any thoughts???
Zalicus Inc. (Nasdaq Capital Market: ZLCS) today announced that it has filed a Certificate of Amendment to its Sixth Amended and Restated Certificate of Incorporation, with the Secretary of State of the State of Delaware to effect a 1-for-6 reverse stock split of Zalicus common stock, effective as of October 3, 2013 at 12:01 a.m. Eastern Time. The Certificate of Amendment to effect a reverse stock split was approved by the company’s stockholders at its Annual Meeting of Stockholders held on June 6, 2013 and the specific 1-for-6 ratio was subsequently approved by the Zalicus Board of Directors on September 18, 2013. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 147.5 million to approximately 24.6 million. As a result of the reverse stock split, Zalicus expects to regain compliance with the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Capital Market.
I would have to believe that Mgt. will do everything they can to get the PPS above $.10 (or they wont get majority of their funding).
Interesting thought! I believe this is an excellent idea...and badly needed....too much confusion with the latest financings.
Also, Gerald is beginning to get into more of a "Over promise" and "Under deliver" precedent. More importantly, I understand things take time...but as the CEO ...don't stand up there at the Rodman & Renshaw conference in late Sep. promising Q3 deliverables...and then you don't deliver nor right size those expectations.
Also, we were promised a second set of Orphan data almost 6 weeks .....if you cant deliver the goods; then don't tarnish your credibility (by setting specific expectations).
Its a really disappointing and frustrating time to be a retail shareholder here. So many great biotech investment opportunities out there....I don't intend to marry any company stock that intends to shaft the retail shareholder base repeatedly.
Incorrect! If we closed at $.06 on Friday; and we are only at intraday trading right now (did not close yet)...when exactly did we break the 200 day moving avg?
No! Of the potential $11mm in financing; the trigger to transact at least $8mm (of the financing deals) requires a PPS of over $.10. So essentially; Mgt. is extremely motivated to release very good news.
Also, the investors have the option to resale their securities; it doesn't mean they will do partially or in full.
So much mis-information being shared on this board. Please make sure to do your own Due diligence.
Has Jason literally confirmed that he is releasing an updated report. Or is that your speculation?
In regards to dilution; this info. was copied directly from the S-1:
Note: the investors have the option to convert the Debentures in whole or in part....so the reality that our PPS is fully diluted is pure nonsense.
At any time after the Original Issue Date and until the Debentures are no longer outstanding, the Debentures shall be convertible, in whole or in part, into shares of Common Stock at the option of the Investors, subject to certain conversion limitations set forth in the Debentures. The conversion price for the Debentures is $0.04 per share, subject to adjustments upon certain events, as set forth in the Debentures. Interest on the Debentures accrue at the rate of 8% annually and is payable on any redemption, conversion and at maturity. Interest is payable in cash or at the Company’s option in shares of the Company’s common stock; provided certain conditions are met. Commencing on the 9 month anniversary and every 10 Trading days thereafter, the Company will be obligated to redeem a certain amount under the Debenture (the “Monthly Redemption”) until the full redemption of the Debenture. The first 8 Monthly Redemptions shall equal 5% of the original principal amount of the Debentures and thereafter the Monthly Redemption shall equal 15% of the original principal amount. In lieu of cash redemption and subject to the Company meeting certain equity conditions described in the Debenture, the Company may elect to pay the Monthly Redemptions in shares of Common Stock as provided in the Debenture.
Here you go......
Per Gerald:
"The proceeds from this second closing will allow the Company to achieve additional milestones for its MANF and LymPro programs, including the development of collaborations with major research institutions currently conducting research on MANF, as well as complete additional clinical studies for LymPro as we move it towards commercialization," said Gerald E. Commissiong, President & CEO of Amarantus. "Most importantly, assuming the full exercise of the warrants in this financing if our common shares trade above $0.10, management believes the Company should meet the listing standards required to up-list to a national exchange without the need to raise additional capital. With the full exercise of the warrants, the Company will have sufficient capital to operate into 2015."
From the Yahoo MB:
VERY IMPORTANT!!!! Please note that majority of the Dilution will not occur until the PPS goes over $.10 (which is in the form of exercisable and convertible warrants). Therefore, we held ground fairly well Friday for a reason (we only have some minor dilution; the warrants have not be converted yet).
Gerald responded to a concerned shareholder and shared the response below:
Dear Shareholder,
"is simply registering shares that have already been sold in the two previously announced private placements $1.4M and $1.6M totaling $3M, and the attached warrants. This is not additional dilution than what was already announced."
Gerald
P.S. PAY ATTENTION to the totals 1.3+1.4= 3million
THE WARRANTS, about 8million dollars worth are all over .10! Who is behind a great deal of these WARRANTS - AMARANTUS INSIDERS...Read between the lines.
From the Yahoo MB:
VERY IMPORTANT!!!! Please note that majority of the Dilution will not occur until the PPS goes over $.10 (which is in the form of exercisable and convertible warrants). Therefore, we held ground fairly well Friday for a reason (we only have some minor dilution; the warrants have not be converted yet).
Gerald responded to a concerned shareholder and shared the response below:
Dear Shareholder,
"is simply registering shares that have already been sold in the two previously announced private placements $1.4M and $1.6M totaling $3M, and the attached warrants. This is not additional dilution than what was already announced."
Gerald
P.S. PAY ATTENTION to the totals 1.3+1.4= 3million
THE WARRANTS, about 8million dollars worth are all over .10! Who is behind a great deal of these WARRANTS - AMARANTUS INSIDERS...Read between the lines.
True! Leverage and negotiating power will reward and yield a nice return. PATIENCE!!!
Agree sir. I think today was a rather important victory; it closed red but to hold the 200 day and stay above $.06 probably surprised a lot of investors.
Most importantly, we are not fully diluted as the many of the warrants wont trigger until above $.10. Moreover, the LymPro news looks like a big win for us next week.
Lastly, I think investors will get blow away when the MANF programs really kick in....we know a Parkinsons IND is on the way in 2014 (how many others too)?
The recent cash raises and timing of this offering (leading up to LymPro news) have a purpose (to accelerate future success but at a S/T cost). More importantly, the company management seem extremely motivated to have a sufficient capital structure to Uplist (and now maybe in a hurry).
Dilution is never a good thing; however, if we have to take a step back to take 10 steps forward so be it. Just a reminder; the S-1 is a securities offering and DOES NOT indicate or guarantee that the maximum amount of shares will be issued, exercised and money raised.
Note: Just one theory....perhaps this story has something to do with the the constant selling pressure that we have witnessed over the last few months and is not directly related to the shorts. It always amazes me how the PPS has continuously suffered constant selling pressure (as these sellers have been liquidating...and the upside here is to remove this selling pressure or constraint and absorb there shares)...which will eventually lead to a steadier rise for our PPS.
Just my two cents; still cautiously optimistic (but the overnight windfall wont happen anymore; it will be more of a grinding upward movement).
From the S-1 (the good stuff is outlined below); they are targeting an IND for Parkinson's in the 2nd half of 2014
DEVELOPMENT PLAN
The Company intends to focus on developing MANF as a therapeutic protein for Parkinson’s disease with the intention of gaining Investigational New Drug Status with the FDA in order to initiate human clinical studies in the United States in the second half of 2014. Amarantus intends to perform animal proof-of-concept studies in the areas of Myocardial Infarction, Traumatic Brain Injury and Organ Transplantation. In addition over the next 12 months, the Company intends to focus its product development efforts on the establishment of GMP-grade material and MANF’s safety profile through toxicology studies in order to gain regulatory approval to initiate human clinical studies. This will provide the experimental rationale for moving forward into human clinical studies for the treatment of Parkinson’s disease. The Company will also evaluate additional indications for MANF.
For the next 12 months, the Company intends to focus the diagnostic development of LymPro on gaining regulatory approval to initiate commercial sales of LymPro as a Laboratory Developed Test (“LDT”) under the Clinical Laboratory Improvement Amendments (“CLIA”). The Company intends to initiate an initial clinical study in the first half of 2013 to confirm methods previously published in scientific journals, and begin a Phase 2 validation study to support LDT status in the second half of 2013
We are not fully diluted (just yet). Please read below; I can only imagine that this must be Dominion (as who else can be selling large blocks of stock). You will get a very strong indication on how fully diluted our PPS will be ....based on the opening price tomorrow.
BTW: An S-1 offering is a registration process that authorizes an issuance of shares (doesn't mean they will be fully transacted). My curiousity; if things are so good S/T; why would any shareholder sell....so I believe there wont be any LymPro deal with BD (the writing appears to be on the wall). In summary; it sounds like Gerald (and company) are going it alone ...and I only pray the validation results are not a huge disappointment.
See below:
The Resale Shares may be sold by the Selling Shareholders to or through underwriters or dealers, directly to purchasers or through agents designated from time to time. For additional information regarding the methods of sale you should refer to the section entitled “Plan of Distribution” in this Prospectus.
I don't disagree with you; but the 100+ Biomed stocks I follow are mostly red (high risk, high beta stocks don't perform very well in markets that are dropping significantly).
The PPS news was good and meaningful; but it wont impact the company for a year plus (so a modest upward movement makes sense to me).
For those disappointed with the PPS reaction (Dow down over 115 points doesn't help either). We are getting each piece of the puzzle one step at a time....it all connects to a bigger picture.
Also, I am very hopeful that quality LymPro news will get the ball rolling.....our PPS is a SLEEPING GIANT.
Answer: I thought the PR was loud and clear = Parkinsons
NEWS (this AM):
Amarantus Enters Into Letter of Intent With Renishaw for Convection-Enhanced Delivery of MANF in Parkinson's Disease
Download PDF
SUNNYVALE, Calif., Oct. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced that it has entered into a letter of intent (the "LOI") with Renishaw PLC for the use of Renishaw's proprietary implantable neurosurgical products and systems, including the neuromate® stereotactic robot, neuroinspire™ surgical planning software, and neuroinfuse™ - intraparenchymal delivery system for the delivery of MANF in Parkinson's disease and other neurological conditions. Over the course of the next 12 months, the companies will collaborate to conduct certain feasibility studies to ensure the long-term viability of delivering MANF using Renishaw's product line to key brain structures. If successful, the companies expect to enter into a definitive agreement to support human clinical studies and commercial use.
Concurrently, Amarantus released the complete final report from certain neurorestoration 6-OHDA models of Parkinson's disease demonstrating MANF's ability to re-innervate the striatum following nigral injection. A copy of the report is available at: http://www.sec.gov/Archives/edgar/data/1424812/000114420413053638/v356539_ex99-1.htm.
About Amarantus
Amarantus is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
CONTACT: Investor/Media Contacts
Russell Miller, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408.737.2734 x 109
ir@amarantus.com
Thanks JPetro....great information. I thought the Santhera (LID)drug information that I posted was interesting; as they have stated they want a partner to move it forward and commercialize it.
Could you imagine what decisions Gerald has to make each day; where does he focus and start this journey (MANF has all the signs of being a blockbuster drug).
Ophthalmology (Dry AMD) is going to be a huge market opportunity for MANF:
We believe RP is just the beginning of the MANF story in ophthalmology. Other neurotrophic factors have begun to show promise in many diseases in the area and the data announced earlier this week scientifically supports development in many therapeutic indications beyond RP in ophthalmology, including Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD affects approximately 15 million people in the United States. 14%-24% of the U.S. population age 65-74 years and 35% of people aged 75 years or older have the disease[1]. Currently, there are no available disease-modifying treatments for Dry AMD, making the opportunity for MANF so attractive. MANF’s development in RP may accelerate the pathway for it to reach the significantly larger Dry AMD patient population by proving cone and rod protection in humans in the smaller RP population first.
Ophthalmology has taken on significantly greater interest as of late from major players in the biopharmaceutical industry: Pfizer Inc. (PFE), Allergan Inc. (AGN), Alcon Inc. (ACL), Novartis AG (NVS), Merck & co. Inc. (MRK) and Roche (RHHBY) cover approximately 70% of the $10 billion market. The primary reason why the ophthalmology market is currently so small is very simple: very few effective disease-modifying treatments exist. Interestingly, the FDA notes that only 21 new drugs were approved in the last 10 years, suggesting a significant lack of breakthrough biology in this space, as evidenced by these companies’ thin ophthalmology pipelines. What’s more, these companies have primarily added drug candidates to their pipelines through in-licensure and strategic transactions, making the opportunity even more appealing for Amarantus. There is no question that the medical outcome of new, truly disease-modifying treatments in the area will have a meaningful impact on patients’ lives; being able to see versus being blind is a massive improvement in quality of life that would undoubtedly be highly coveted by patients, caregivers and physicians.
After positive Phase IIb results in the treatment of levodopa (L-dopa) induced dyskinesia in Parkinson’s disease (DPD), Santhera is now intending to build a partnership for further
development and commercialization of Fipamezole.
A future licensee:
?? will develop and commercialize the product
?? will have the the right to use all data generated by Santhera for development and commercialization
?? may license worldwide rights, but territory of interest to be negotiated
Fipamezole for treatment of levodopa (L-dopa) induced dyskinesia in Parkinson’s disease (DPD) 700+ mio USD peak sales first-in-class opportunity for US + EU ready to enter phase III.
Levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. Amarantus has a Phase 2b candidate (that was In licensed and will be moving forward in about 6 months).
Adamas Pharmaceuticals reports positive results from ADS-5102 Phase 2/3 EASED clinical trial
Published on October 2, 2013 at 12:37 PM ·
Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED™ clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) patients. ADS-5102 met its primary endpoint in the Phase 2/3 clinical trial and demonstrated statistically significant improvements in a number of key assessments of LID.
"We are extremely pleased with the positive results achieved in our Phase 2/3 EASED trial, and the magnitude of the change in ON time without troublesome dyskinesia in Parkinson's patients suffering from LID. Levodopa-induced dyskinesia is one of the most difficult challenges facing patients with PD, and there are no FDA-approved drug treatments available," said Gregory T. Went, Ph.D., Chief Executive Officer of Adamas. "ADS-5102 reduced both the duration and severity of dyskinesia among PD patients with statistical significance, providing an average of 11.5 hours during the day of ON time without troublesome dyskinesias as compared to 8 hours on placebo. The encouraging data from this trial indicate that ADS-5102 has the potential to positively impact the lives of PD patients and we are moving forward on the remaining NDA-enabling activities."
Continued on Next page >>
Excellent DD!!! BD has to dot the I's and cross the T's. Proper signoffs, legal review, Executive sponsorship approval. Its all looking great for LymPro.
But MANF is what intrigues me (and many). I would like to see some timelines as to when the 1st IND will happen (maybe by the end of Q1 or Q2 (next year). And the Orphan strategy is huge...Retinosis Pigmentosis is a 10 billion dollar market (with virtually no competition).
It is my understanding that Gerald knew the validation results a while ago. What not clear; is if the two parties are negotiating a possible deal.
Actually, I can quote the gentleman who met Gerald on Saturday (at the Conference); as saying that "we have moved on from focusing on the validation results" ....to focusing and making LymPro the gold standard in the industry. More importantly, I am extremely confident those validated results were finalized a while ago (we will know when its the right time...which should be by early next week).